CMV infection and glioma, a highly controversial concept struggling in the clinical arena

Neuro-Oncology

Volumn 16, Issue 3, 2014, Pages 332-333

  Wick, Wolfgang ^a,b   Platten, Michael ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BRAIN NEOPLASMS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; GLIOBLASTOMA; HUMANS;

EID: 84894262588     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou002     Document Type: Short Survey

References (18)

1. Sinclair J. Human cytomegalovirus: Latency and reactivation in the myeloid lineage. Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology. 2008;41:180-185.
2. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Reviews in Medical Virology. 2010;20:202-213.
3. Sanders VJ, Felisan S, Waddell A, et al. Detection of herpesviridae in postmortem multiple sclerosis brain tissue and controls by polymerase chain reaction. J Neurovirol. 1996;2:249-258.
4. Dziurzynski K, Chang SM, Heimberger AB, et al. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol. 2012;14: 246-255.
5. Stragliotto G, Rahbar A, Solberg NW, et al. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study. Int J Cancer. 2013;133:1204-1213.
6. Soderberg-Naucler C, Rahbar A, Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. The New England Journal of Medicine. 2013;369:985-986.
7. Soderberg-Naucler C, Peredo I, Rahbar A, et al. Use of Cox regression with treatment status as a time-dependent covariate to re-analyze survival benefit excludes immortal time bias effect in patients with glioblastoma who received prolonged adjuvant treatment with valganciclovir. [published online ahead of print January 6, 2014]. Int J Cancer. 2014. doi:10.1002/ijc.28663.
8. Liu CJ, Hu YW. Immortal time bias in retrospective analysis: Is there a survival benefit in patients with glioblastoma who received prolonged treatment of adjuvant Valganciclovir? [published online ahead of print January 6, 2014]. Int J Cancer. 2014. dou:10.1002/ijc.28664.
9. WickW, Wick A, Platten M. Good maths is needed to understand CMV data in glioblastoma. [published olnine ahead of print November 18, 2013]. Int J Cancer. 2013. doi:10.1002/ijc.28614.
10. Wick W, Wick A, Platten M. Challenging cytomegalovirus data in glioblastoma. Neuro Oncol. 2014;16:165.
11. Cobbs CS, Harkins L, Samanta M, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002;62:3347-3350.
12. Sabatier J, Uro-Coste E, Pommepuy I, et al. Detection of human cytomegalovirus genome and gene products in central nervous system tumours. Br J Cancer. 2005;92:747-750.
13. Lau SK, Chen YY, ChenWG, et al. Lack of association of cytomegalovirus with human brain tumors. Mod Pathol. 2005;18:838-843.
14. Hellstrand K, Martner A, Bergstrom T. Valganciclovir in patients with glioblastoma. The New England Journal of Medicine. 2013;369:2066.
15. Tang KW, Alaei-Mahabadi B, Samuelsson T, et al. The landscape of viral expression and host gene fusion and adaptation in human cancer. Nature Communications. 2013;4:2513.
16. Cinatl J Jr., Cinatl J, Vogel JU, et al. Modulatory effects of human cytomegalovirus infection on malignant properties of cancer cells. Intervirology. 1996;39:259-269.
17. Cobbs CS, Soroceanu L, Denham S, et al. Modulation of oncogenic phenotype in human glioma cells by cytomegalovirus IE1-mediated mitogenicity. Cancer Res. 2008;68:724-730.
18. Price RL, Song J, Bingmer K, et al. Cytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations. Cancer Res. 2013;73:3441-3450.